Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 398,900 shares, a growth of 13.8% from the October 15th total of 350,600 shares. Based on an average trading volume of 116,700 shares, the short-interest ratio is currently 3.4 days.

Hedge Funds Weigh In On Harvard Bioscience

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Harvey Partners LLC lifted its holdings in shares of Harvard Bioscience by 6.2% in the 3rd quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock valued at $7,303,000 after acquiring an additional 157,500 shares during the last quarter. Vanguard Group Inc. raised its position in Harvard Bioscience by 2.4% during the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after purchasing an additional 49,576 shares during the period. Royce & Associates LP lifted its stake in shares of Harvard Bioscience by 0.7% in the 3rd quarter. Royce & Associates LP now owns 1,451,450 shares of the medical instruments supplier’s stock valued at $3,904,000 after purchasing an additional 10,000 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Harvard Bioscience by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock worth $2,455,000 after purchasing an additional 19,972 shares during the period. Finally, Meros Investment Management LP increased its position in shares of Harvard Bioscience by 1.6% during the 2nd quarter. Meros Investment Management LP now owns 835,213 shares of the medical instruments supplier’s stock valued at $2,380,000 after purchasing an additional 13,421 shares during the last quarter. 80.87% of the stock is owned by hedge funds and other institutional investors.

Harvard Bioscience Price Performance

Shares of NASDAQ HBIO traded up $0.08 during midday trading on Monday, reaching $2.22. 43,356 shares of the stock traded hands, compared to its average volume of 116,860. The company’s 50 day moving average is $2.52 and its 200 day moving average is $2.89. Harvard Bioscience has a one year low of $2.12 and a one year high of $5.56. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.94. The stock has a market capitalization of $96.83 million, a PE ratio of -6.67 and a beta of 1.31.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.